Erica N Lamkin

Targeting Bruton’s Tyrosine Kinase in CLL: Selectivity, Resistance Mechanisms, and Emerging Therapeutic Strategies

A summary of the design of irreversible inhibitors, reversible inhibitors, and Proteolysis-targeting chimera (PROTAC) degraders targeting BTK is provided and how the design of these inhibitors and PROTACs leads to a more selective inhibition and degradation of BTK is reviewed.